0001104659-17-072152.txt : 20171206 0001104659-17-072152.hdr.sgml : 20171206 20171206205525 ACCESSION NUMBER: 0001104659-17-072152 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20171206 FILED AS OF DATE: 20171206 DATE AS OF CHANGE: 20171206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: bioMerieux/ADR CENTRAL INDEX KEY: 0001653191 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38319 FILM NUMBER: 171243376 BUSINESS ADDRESS: STREET 1: CHEMIN DE L'ORME CITY: MARCY L'ETOILE STATE: I0 ZIP: 69280 BUSINESS PHONE: 212-336-2301 MAIL ADDRESS: STREET 1: C/P PATTERSON BELKNAP C/O H. RASPE STREET 2: 1133 AVENUE OF THE AMERICAS CITY: NEW YORK STATE: NY ZIP: 10036 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Quanterix Corp CENTRAL INDEX KEY: 0001503274 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 208957988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 113 HARTWELL AVE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-301-9400 MAIL ADDRESS: STREET 1: 113 HARTWELL AVE CITY: LEXINGTON STATE: MA ZIP: 02421 3 1 a3.xml 3 X0206 3 2017-12-06 0 0001503274 Quanterix Corp QTRX 0001653191 bioMerieux/ADR CHEMIN DE L'ORME MARCY-L'ETOILE I0 69280 FRANCE 0 0 1 0 Series C Preferred Stock Common Stock 2055632 D These shares are convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, at any time after the issuance of such shares, at the holder's election. Not applicable. The shares of preferred stock will convert into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock will convert on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. Exhibit 24.1 - Power of Attorney /s/ Brian Keane, Attorney-in-Fact for bioMerieux S.A. 2017-12-06 EX-24.1 2 ex-24d1.htm EX-24.1

Exhibit 24.1

 

POWER OF ATTORNEY

 

Know all by these presents, that the undersigned hereby constitutes and appoints Joseph Driscoll, Chief Financial Officer of Quanterix Corporation (the “Company”), Ernest Orticerio, Senior Vice President, Finance and Corporate Development of the Company, Brian Keane, General Counsel of the Company, and Megan Gates, John Condon, Brian Shea and Allyson Wilkinson, each of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly, with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

 

(1)                                 execute for and on behalf of the undersigned, forms and authentication documents for EDGAR Filing Access;

 

(2)                                 do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents;

 

(3)                                 execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

 

(4)                                 do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

 

(5)                                 take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact, on behalf of the undersigned pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 1st day of December 2017.

 

 

BIOMÉRIEUX S.A.

 

 

 

By:

/s/ Alexandre Mérieux

 

Name:

Alexandre Mérieux